About Our Company

        

Our History


Feb.2000  Founded Renascience Inc. as an academic bio-venture company in Kanagawa, Japan
Oct.2002  Megsin project adopted as a university-launched R&D program by the Ministry of Economy, Trade and Industry (METI)
Oct.2005 PAI-1 project adopted as a university-launched R&D program by New Energy and Industrial Technology Development Organization (NEDO)
Dec.2010 Established Project PM Co., Ltd. (a special purpose company / subsidiary) and started the first phase 2 trial (investigator-initiated trial) for schizophrenia in collaboration with Tokyo Metropolitan Matsuzawa Hospital
Oct.2012 PAI-1 project adopted as an A-STEP funding program by Japan Science and Technology Agency (JST)
Feb.2014 Pyridoxamine licensed to Kowa Company Ltd. on schizophrenia
May2014 Head office relocated to Chuo-ku, Tokyo
Oct.2014 PAI-1 cancer project adopted as an A-STEP funding program by Japan Science and Technology Agency (JST)
Oct.2016 License agreement with Eirion Therapeutics, Inc., USA on RS5441/RS5484 for dermatological indications
Aug.2017 Initiated an investigator-initiated phase 2a study on CML
Oct.2017 Kowa initiated a phase 2b clinical study on schizophrenia
Nov.2017 Aging Project published in The New York Times (collaboration with Northwestern University School of Medicine)
Jan.2018 Merged Project PM Co., Ltd. Into Renascience Inc.
Jan.2018 Initiated an investigator-initiated clinical trial on ultra-fine endoscopy
Feb.2018 Raised capital through third-party stock issuance (Series A)
2018年 Initiated a phase 2 investigator-initiated clinical study on autism with 13 centers including Tohoku University
Mar.2019 Raised capital through third-party stock issuance (Series B)
Aug.2019 Initiated a phase 2 investigator-initiated clinical study on CML
Dec.2019 Adopted as an AMED’s Cyclic Innovation for Clinical Empowerment (CiCLE) program
Dec.2019 Concluded an option agreement with ASUKA Pharmaceutical Co., Ltd. for a license agreement of pyridoxamine on premenstrual syndrome / premenstrual dysphoric disorder